The PI3K pathway is the most frequently altered pathway in cancer, and its activation has been shown to confer resistance to endocrine and HER2-targeted therapies preclinically.
Ingrid A. Mayer, MD, MSCI
Advertisement
Articles by Ingrid A. Mayer, MD, MSCI
Advertisement
Latest Updated Articles
Development of PI3K Inhibitors in Breast CancerNovember 7th 2014
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
3
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5